P0865: Impact of assay on the predictive performance of model-informed precision dosing of ustekinumab in patients with Crohn’s diseaseECCO'25Year: 2025
Authors: Zhang, W.(1)*;Dervieux, T.(2);Thomas, D.(1);Ferrante, M.(3,4);Vermeire, S.(3,4);Dreesen, E.(1);
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)Prometheus Laboratories, Prometheus Laboratories, San Diego, United States;(3)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;
[1] Verdon et al.J Can Assoc Gastroenterol. 2020;4(2):73-77.
[2] Wang et al. Br J Clin Pharmacol. 2022;88(1):323-335.
P0866: Upadacitinib improves symptomatic, biochemical, and intestinal ultrasound parameters in active UC patients up to one year after treatment induction – one year interim results from the IBD-DACH study EUROPEECCO'25Year: 2025
Authors: Zeissig, S.(1,2)*;Schmelz, R.(1);Helwig, U.(3,4);Moschen, A.R.(5);Greuter, T.(6);Fischer, I.(7);Hammer, L.(8);Rath, S.(8);Kucharzik, T.(9);Maaser, C.(10);
(1)Technische Universität TU Dresden, Department of Medicine I and Center for Regenerative Therapies Dresden, Dresden, Germany;(2)University Medicine Greifswald, Department of Internal Medicine A, Greifswald, Germany;(3)Gastroenterolgoy Practice, Gastroenterolgoy Practice, Oldenburg, Germany;(4)University of Kiel, University of Kiel, Kiel, Germany;(5)Johannes Kepler University of Linz, Department of Internal Medicine 2, Linz, Austria;(6)GZO AG Spital Wetzikon, Department of Gastroenterology, Wetzikon, Switzerland;(7)Biostatistik-Tuebingen, Biostatistik-Tuebingen, Tuebingen, Germany;(8)AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany;(9)University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany;(10)University Teaching Hospital Lueneburg, Outpatients Department Gastroenterology, Lueneburg, Germany;
- 1. Current SmPC Upadacitinib
P0867: Persistence of treatment effect in patients with Ulcerative Colitis and Crohn’s disease: Long-term results from the VISIBLE OLE studyECCO'25Year: 2025
Authors: Vermeire, S.(1)*;Jones, S.(2);Velazco, N.(2);Agboton, C.(2);Wojtowicz, A.M.(2);Young, L.(2);Phillips, R.(3);Loftus- Jr., E.V.(4);Danese, S.(5);D’Haens, G.(6);
(1)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(2)Takeda Pharmaceuticals, Takeda Development Center Americas- Inc., Cambridge, United States;(3)GI PROS Inc., GI PROS Inc., Naples, United States;(4)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(5)IRCCS Ospedale San Raffaele- Università Vita-Salute San Raffaele, Division of Gastroenterology and Gastrointestinal Endoscopy, Milan, Italy;(6)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;
P0868: Long term outcomes from UK mesenchymal stem cell therapy for perianal fistulising Crohn’s disease: a 5 Year follow upECCO'25Year: 2025
Authors: AnandMr, E.(1)*;Rea, B.(2);Iqbal, N.(1);Sayers, A.(3);Hart, A.(4);Lung, P.(5);Brown, S.(3);Tozer, P.(1);
(1)St Mark's The National Bowel Hospital, Colorectal Surgery, London, United Kingdom;(2)Sheffield Teaching Hospitals NHS Foundation Trust, Radiology, Sheffield, United Kingdom;(3)Sheffield Teaching Hospitals NHS Foundation Trust, Colorectal Surgery, Sheffield, United Kingdom;(4)St Mark's The National Bowel Hospital, Gastroenterology, London, United Kingdom;(5)St Mark's The National Bowel Hospital, Radiology, London, United Kingdom;
1. Anand, Easan, Devi, Jalpa, Joshi, Shivani, et al. Consensus definition of a radiologically healed fistula on magnetic resonance imaging in perianal Crohn’s disease: an international Delphi study. BMJ Open; 0:e087919. DOI:10.1136/bmjopen-2024-087919.
2. Hindryckx P, Jairath V, Zou G, et al. Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn’s Disease. Gastroenterology 2019; 157: 1233-1244.e5.
3. Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20: 27–32.
4. Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut 1999; 44: 77–80.
5. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003; 98: 332–9.
P0869: Model-informed dosage de-escalation of infliximab in patients with inflammatory bowel diseasesECCO'25Year: 2025
Authors: Wang, Z.(1);De Greef, I.(2,3);Kantasiripitak , W.(1);Wicha, S.G.(4);Tops, S.(1);Nigro, M.(2);Outtier, A.(2);Verstockt, B.(2,3);Sabino, J.(2,3);Thomas , D.(1);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1)*;
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)University of Hamburg, Department of Clinical Pharmacy, Hamburg, Germany;
P0871: Textbook Outcomes in Acute Severe Ulcerative Colitis: A Novel Approach to Assessing Patient Quality of Care in Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Wu, M.Y.(1,2);Nario, S.(1)*;Tung, C.(1);Kiely, C.(1);
(1)Royal North Shore Hospital, Department of Gastroenterology, St Leonards, Australia;(2)University of Sydney, Faculty of Medicine, Sydney, Australia;
1. Naumann DN, Bhangu A, Brooks A, et al. A call for patient-centred textbook outcomes for emergency surgery and trauma. Br J Surg. 2022;109(12):1191. doi:10.1093/BJS/ZNAC271
2. Tsilimigras DI, Pawlik TM, Moris D. Textbook outcomes in hepatobiliary and pancreatic surgery. World J Gastroenterol. 2021;27(15):1524. doi:10.3748/WJG.V27.I15.1524
3. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/GUTJNL-2019-318484
4. Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13(3):273-284. doi:10.1093/ECCO-JCC/JJY114
P0872: Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn’s disease: Phase 3 GRAVITI study results through week 48ECCO'25Year: 2025
Authors: Hart, A.(1)*;Panaccione, R.(2);Steinwurz, F.(3);Cao, Q.(4);Hisamatsu, T.(5);Nancey, S.(6);Olurinde, M.(7);Yang, Z.(8);Merrall, E.(9);Terry, N.A.(7);Sands, B.E.(10);
(1)London North-West University Healthcare NHS Trust, Medicine, London, United Kingdom;(2)University of Calgary, Medicine, Calgary, Canada;(3)Hospital Israelita Albert Einstein, Medicine, São Paulo, Brazil;(4)Sir Run Run Shaw Hospital Affiliated with School of Medicine- Zhejiang University, Medicine, Hangzhou, China;(5)Kyorin University, Medicine, Tokyo, Japan;(6)Hospices Civils de Lyon- Hôpital Lyon Sud, Medicine, Lyon, France;(7)Janssen Research & Development- LLC, Immunology, Spring House, United States;(8)Janssen Research & Development- LLC, Statistics, Spring House, United States;(9)Janssen Vaccines & Prevention B.V., Biostatistics, Leiden, The Netherlands;(10)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Medicine, New York, United States;
P0873: Risk factors for difficult endoscopic bowel dilatation of strictures among patients with inflammatory bowel disease (IBD): Findings from a IBD tertiary centers in Poland and Czech Republic.ECCO'25Year: 2025
Authors: LewandowskiM.D., K.(1)*;Lukas, M.(2,3);Kaniewska, M.(1);Tulewicz-Marti, E.(1);Karłowicz, K.(1);Bednarczuk, A.(1);Kolar, M.(2);Jirsa, J.(2);Lukas, M.(2);Rydzewska, G.(1,4);
(1)National Medical Institute of the Ministry of the Interior and Administration, Department of Gastroenterology and Internal Medicine, Warsaw, Poland;(2)ISCARE a.s., IBD Clinical and Research Center, Prague, Czech Republic;(3)Charles University and Kralovske Vinohrady University Hospital, Department of Surgery- 3rd Faculty of Medicine, Prague, Czech Republic;(4)Jan Kochanowski University, Collegium Medicum, Kielce, Poland;
P0874: Efficacy and tolerability of anti-tumor necrosis factor alpha therapy in refractory intestinal Behçet’s diseaseECCO'25Year: 2025
Authors: Chang, J.Y.(1)*;Soo Jung , P.(2);Jae Jun , P.(2);Tae Il , K.(2);Jae Hee , C.(2);Jihye , P.(2);
(1)Ewha Womans University Seoul hospital, Division of Gastroenterology- Department of Health Promotion Center, Seoul, Korea- Republic Of;(2)Yonsei University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;
1. Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol 2014;49(1):156-62.
2. Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95(24):e3863.
3. Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab. Dig Dis Sci 2017;62(2):441-7.
4. Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet's disease in the open label study following a phase 3 clinical trial. Intest Res 2017;15(3):395-401.
P0876: One-year effectiveness and safety of ustekinumab treatment in patients with ulcerative colitis: An Asan-Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD) multicentre real-world cohort studyECCO'25Year: 2025
Authors: Baek, J.E.(1,2)*;Kim, M.K.(1);Kim, E.S.(3);Kim, K.O.(4);Jo, H.H.(5);Hwang, S.W.(1,6);Park, S.H.(1,6);Jang, B.I.(4);Kim, E.Y.(5);Yang, S.K.(1,6);Kim, S.K.(3);Ye, B.D.(1,6);
(1)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology, Seoul, Korea- Republic Of;(2)St. Vincent's Hospital- College of Medicine- The Catholic University of Korea, Department of Internal Medicine, Suwon, Korea- Republic Of;(3)School of Medicine- Kyungpook National University, Department of Internal Medicine, Daegu, Korea- Republic Of;(4)Yeungnam University College of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(5)Daegu Catholic University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(6)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P0878: Early lymphocytosis is a novel predictor of response to rescue infliximab in acute severe ulcerative colitis: results from PREDICT-UCECCO'25Year: 2025
Authors: Con, D.(1);Choy, M.(1);Li Wai Suen, C.(1)*;Boyd, K.(1);Pena, R.(1);Burrell, K.(1);Rosella, O.(1);Proud, D.(1);Brouwer, R.(1);Gorelik, A.(2);Liew, D.(3);Connell, W.(4);Wright, E.(4);Taylor, K.(5);Pudipeddi, A.(6);Sawers, M.(7);Christensen, B.(8);Ng, W.(9);Begun, J.(10);Radford-Smith, G.(11);Garg, M.(12);Martin, N.(13);van Langenberg, D.(14);Ding, N.(4);Beswick, L.(7);Leong, R.(6);Sparrow, M.(5);De Cruz, P.(1);
(1)Austin Health, Department of Gastroenterology, Melbourne, Australia;(2)Monash University, School of Public Health and Preventive Medicine, Melbourne, Australia;(3)University of Adelaide, Department of Medicine, Adelaide, Australia;(4)St Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(5)Alfred Health, Department of Gastroenterology, Melbourne, Australia;(6)Concord Hospital, Department of Gastroenterology, Sydney, Australia;(7)Barwon Health, Department of Gastroenterology, Geelong, Australia;(8)Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(9)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(10)Mater Hospital, Department of Gastroenterology, Brisbane, Australia;(11)Royal Brisbane and Women's Hospital, Department of Gastroenterology, Brisbane, Australia;(12)Northern Health, Department of Gastroenterology, Melbourne, Australia;(13)Princess Alexandra Hospital, Department of Gastroenterology, Brisbane, Australia;(14)Eastern Health, Department of Gastroenterology, Melbourne, Australia;
1Choy MC, Li Wai Suen CFD, Con D, et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9(11): 981-96.
P0879: The totality of evidence for FYB202 – an EU-approved and US-licensed biosimilar to reference ustekinumabECCO'25Year: 2025
Authors: Balser, S.(1)*;Freudensprung, B.(2);Huebner, K.(3);Moreau, I.(4);Nopora, K.(1);Pippig, S.(4);Schmid, M.(5);Trieb, M.(6);Wolschin, F.(7);
(1)Formycon AG, Clinical Development & Operations, Planegg/Martinsried, Germany;(2)Formycon AG, Business Development and Licensing, Planegg/Martinsried, Germany;(3)Formycon AG, Project Analytics, Planegg/Martinsried, Germany;(4)Formycon AG, Bioanalytics, Planegg/Martinsried, Germany;(5)Formycon AG, Functional Characterization, Planegg/Martinsried, Germany;(6)Formycon AG, Regulatory Affairs, Planegg/Martinsried, Germany;(7)Formycon AG, Protein & Process Sciences, Planegg/Martinsried, Germany;
1. Balser, S., Nopora, K., Körner, J., Wedemeyer, R.-S., Anschütz, M. and Schug, B. (2024), New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double-Blind, Parallel-Group, Single-Dose Trial in Healthy Subjects. Clin Pharmacol Drug Dev.; https://doi.org/10.1002/cpdd.1473
2. Papp, K., Balser, S., Nopora, K., Freudensprung, B., Trieb, M. (2024), A randomised, double-blind trial to compare the efficacy, safety, and immunogenicity of the proposed biosimilar ustekinumab (FYB202) with reference ustekinumab in patients with moderate-to-severe plaque psoriasis. EADV 2024, Poster PO984
P0880: Sphingosine 1-phosphate (S1P) Receptor Modulators for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsECCO'25Year: 2025
Authors: Campedelli, L.(1)*;Antunes, V.(2);Perim, V.(3);Marinho, A.(4);Junkes Milioli, N.(5);
(1)Boston University/Boston Medical Center, Internal Medicine, Boston- MA, United States;(2)Universidade Federal de Ciencias da Saude de Porto Alegre, Medicine, Porto Alegre- RS, Brazil;(3)University of Alabama at Birmingham, Division of Surgical Oncology- Department of Surgery, Birmingham- AL, United States;(4)Universidade Federal do Estado do Rio de Janeiro, Medicine, Rio de Janeiro- RJ, Brazil;(5)Pontifical Catholic University of Rio Grande do Sul, Department of Gastroenterology and Gastrointestinal Endoscopy, Porto Alegre- RS, Brazil;
1.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. 2023;0(0). doi:https://doi.org/10.1016/S0140-6736(23)00061-2
2.Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. New England Journal of Medicine. 2016;374(18):1754-1762. doi:https://doi.org/10.1056/nejmoa1513248
3.Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 2021;385(14):1280-1291. doi:https://doi.org/10.1056/nejmoa2033617
P0881: Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative ColitisECCO'25Year: 2025
Authors: SinghD.M., A.(1);Midha, V.(2)*;Bhardwaj, A.(1);Sharma, R.(1);Singh, D.(1);Mahajan, R.(1);Sood, A.(1);
(1)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;
P0882: Quality of care in Inflammatory Bowel Disease from Patient’s perspective with QUOTE-IBD: a Greek multicenter prospective studyECCO'25Year: 2025
Authors: Mantaka, A.(1)*;Psistakis, A.(2);Anagnostopoulou, E.(1);Karmiris, K.(2);Theodoropoulou, A.(2);Koutroubakis, I.(3);Apostolakis, I.(4,5);Domeyer, P.R.(5);Sarafis, P.(5,6);
(1)"Saint George" General Hospital of Chania- Crete, Department of Gastroenterology, Chania, Greece;(2)Venizeleio General Hospital, Department of Gastroenterology, Heraklion, Greece;(3)University Hospital of Heraklion, Department of Gastroenterology, Heraklion, Greece;(4)National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;(5)Hellenic Open University, School of Social Sciences, Patras, Greece;(6)University of Thessaly, Department of Nursing, Larissa, Greece;
1.Elkjaer M, Moser G, Reinisch W, et al. IBD patients need in health quality of care ECCO consensus. J Crohns Colitis. 2008;2:181–8.
2. Hanefeld J, Powell-Jackson T, Balabanova D. Understanding and measuring quality of care: dealing with complexity. Bull World Health Organ. 2017;95:368–74.
3. van der Eijk I, Sixma H, Smeets T, et al. Quality of health care in inflammatory bowel disease: development of a reliable questionnaire (QUOTE-IBD) and first results. Am J Gastroenterol 2000;96: 3329–36.
4. Pallis AG, Kostagiolas PA, Mouzas IA, Niakas D. Patients' perceptions as an indicator of quality of care, in Greek patients with inflammatory bowel disease. Scand J Caring Sci. 2009;23(1):93-9.
P0884: Environmental impact and costs of a switching program of intravenous to subcutaneous infliximab in Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Oliveira, R.(1)*;Roseira, J.(1);Araújo, N.(2);Cavaco, C.(1);André, J.(1);Sousa, M.(2);Tavares de Sousa, H.(1);Cunha, M.(3);
(1)Unidade Local de Saúde do Algarve, Gastroenterology Department, Portimão, Portugal;(2)Unidade Local de Saúde do Algarve, Pharmacy Department, Portimão, Portugal;(3)Unidade Local de Saúde do Algarve, Colorectal Group - General Surgery Department, Portimão, Portugal;
